REKAM JEJAK DIGITAL ARTIKEL

THE IMPACT OF COVID-19 ON MORTALITY IN TRAUMA PATIENTS UNDERGOING ORTHOPEDIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Clinical and Experimental Emergency Medicine, 2023

STATUS JURNAL SAAT INI

Scopus Previ	24/	Q Author S	Search Sources ⑦ f	Create account	Sign in
	Source details		Feedback > Compare se	ources >	
	Clinical and Experimental Emergency Medicine Open Access © Scopus coverage years: from 2018 to 2022		CiteScore 2021 2.1	٥	
	Publisher: Korean Society of Emergency Medicine E-ISSN: 2383-4625 Subject are: (Nuning: Emergency Nunsing) (Medicine Emergency Medicine)		5JR 2021 0.409	٥	
	Source type: Journal View all document alert Set document alert Save to source list Source Homepage		SNIP 2021 0.859	٥	
	CiteScore CiteScore rank & trend Scopus content coverage			_	
	Improved CiteScore methodology CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. Learn more >			×	
	CiteScore 2021 CiteScoreTracker 2022 \odot 2.1 = $\frac{398 \text{ Citations 2018 - 2021}}{186 \text{ Documents 2018 - 2021}}$ CiteScoreTracker 2022 \odot 2.4 = $\frac{462 \text{ Citations to date}}{196 \text{ Documents to date}}$ Lut updated on 65 April, 2023 Updated mustify				

Clinical and Experimental Emergency Medicine- Impact Score, Overall Ranking, h-index, SJR, Rating, Publisher, ISSN, and Other Important Metrics

Last Updated on May 27, 2022

Impact Score	h-Index	Rank	SJR
Q 1.32	(H) 10	11870	6.409

UPDATE IMPACT FACTOR JURNAL


Impact Score Trend

Year wise Impact Score (IS) of Clinical and Experimental Emergency Medicine. Based on Scopus data.



SCIMAGO RANK JURNAL

Clinical and Experimental Emergency Medicine 8



SUBMISSION (24 NOV 2022)

$\wedge \vee$		7 🖂	M
ound in Gmail Inbox			-
			1000
our network settings p ad Content	prevent content from loading privat	tely.	
Clinical and E To: Husna Dhar	xperimental Emergency Medic ma Putera >	sine	24/11/23
Clin Exp Emerg 20220172]	g Med] Complete submi	issions. Temporary	v number
	[Clin Exp Emerg	Med] Complete subm	issions.
Sender :	Clinical and Experimental Emergen	cy Medicine	
Recipient :	Husna Dharma Putera		
Date Submitted :	24-Nov-2022 14:13		
Temporary numbe	r: 20220172		
Category of Submission :	New		
Type of Manuscript	t: Systematic review		
Abstract			
The impact of COV	ID-19 on mortality in trauma patie A systematic review and mo	승규님 사람이 다 것 같은 것 같아요. 그 것 아님의 그 것 같아요. 아님의 것 같아.	surgery:
orthopaedic trauma who underwent orth ScienceDirect, the C original publications and Meta-Analyses Joanna Briggs Instii odds ratio (OR). Th inclusion and exclus were the most com 456 positive patien mortality escalation interval 5.92-9.80; rate increased 7.62	bal spread of the COVID-19 pander surgery. This study aims to investig- iopaedic surgery trauma had a higher in ochrane COVID-19 Study Register, and . This study used the 2020 Preferred (PRISMA) 2020. The validity was evalu- tute. The study and participant chara- e data was analyzed using Review Ma sion criteria, 16 eligible articles utilize mon case and pelvic surgery was the in- ts (6.12%) and 134 deaths among a (29.38% vs. 5.3% in negative gro p=0.00001). Conclusions: In COVID-p 2 times. It could be possible to imp entifying risk factors.	ate whether COVID-19 positive risk of post-operative mortality. d MEDLINE via PubMed were see Reporting Items for Systemati uated using a checklist develop cteristics were extracted, as w anager 5.4.1. Results: After ap ed out of 717. Lower extremit most performed intervention. T COVID-positive groups, which pups; odds ratio 7.62, 95% c positive groups, the post-operation	e patients Methods: arched for ic Reviews bed by the vell as the plying the ty injuries here were indicated confidence tive death
operative care by idi			

REVISI DAN RE-REGISTRASI (25 NOV 2022)

~ ~		Ø
Clinical and Exp To: Husna Dharma	perimental Emergency Medicine a Putera >	25/11/
lin Exp Emerg	Med] Manuscript Revision and re-registrati	on
	Manuscript Revision and re-registra	ation
Data Calasiana I		
Date Submitted : Type of Manuscript :	November 24, 2022	
Title :	The impact of COVID-19 on mortality in trauma patients undergoing orthopaedic surgery: A systematic review and meta-analysis	
Dear Dr. Husna Dh		
undergoing orthop	tled "The impact of COVID-19 on mortality in trauma patients baedic surgery: A systematic review and meta-analysis" has been ditorial Office of <i>Clin Exp Emerg Med</i> . However, The following issues are	
	ms as below, your manuscript is now at the stage of incomplete	
- All of the referen citation of ref 6 is	nces should be cited in the main text file. Please note that the in-text missing.	-
- Please include fig	gure legends at the end of the main text file after the references.	-
Please resubmit th Sincerely,	ne manuscritp after revision.	
Sincerely, Adam J Singer, M.I Editor-in-Chief <i>Clin Exp Emerg M</i> e	D.	

REVISI PERTAMA (27 DES 2022-19 JAN 2023)

	r	m	E)				* 68% 🛃	20.20 Ti			~	m	••••	F	F	all ^s	
~ ~	53	5	Q	Ξ			\odot	للك		\sim	5	SCA	Q	-			
Clinical and To: Husna Pu	Experimental era >	Emerge	ncy Me	dicine		27/12	/22			iical and Exp Husna Dharm		Emerge	ency Me	edicine		19/0	1/
anuscript ID vision	[CEEM-22	2-403]	Lette	er of d	ecision 1st	- Major			1st Rev ubmit		npleted] CEEN	1-22-	403 v	vas revised	and	
			2										2				
		[Clin	1 Exp E	merg	Med] Review	result : 1st							Emer	g Med]	1st Revision	completed.	•
Date sent :	December 27, 2	2022								cript ID :	CEEM-22-						
Date Decisioned	: December 27, 2	2022								on Date : f Manuscript :	19-Jan-202						
Manuscript ID :	CEEM-22-403								-	i Manuscript :			19 on m	ortality in	trauma patients ur	deraoina	
Title :					ma patients under d meta-analysis	going			Title :						w and meta-analys		
Corresponding Author :	Husna Putera	90,71,10,	sternation	erien an	a meta analysis				Corres Author	ponding :	Husna Dha	rma Putera	i				
Review result :	Major revision	(Revisi	on Period	t : ~ 202	3-1-23)				Author	's opinion :	#1 reviewe		ata tha #	1	r's time spent read	ing and	
Comments to					,						commentin			Tieviewe	a s time spent read	ing and	
Authors (Editorial Office)											1. We are v on the title		ul for the	thoughtfu	ul comments that y	ou have provided	
•											2. We are v on the abs		ul for the	thoughtfu	ul comments that y	ou have provided	
Dear Author											 We appr very helpfu 	eciate you II.			k on the keywords,		
					le, we would be wi						 We since current situ 				nt remarks about o the study.	ur background,	
					noted in the review bmit your manuscr							eciate you	thought		ents about the appr	oaches, and	
further consid	eration for public	ation.									6. We are v	very gratef	ul for the	thoughtfu	ul comments that y	ou have provided	
Please review point manner		ued by the	reviewers	s and resp	pond to them in a	point-by-					on the obje 7. We appr we find to l	eciate you	r thought	ful remarl	ks on the important	aspects, which	
					o respond to the co										I comments that y revised tables and		
					this space to docu pedite the process						the sugges	tions of the	e #2 and	#3 review	vers.		
revised manu		as specific a	as possibl	e in your	response to the re						impact.				search can have su		
		17.1			3.						 We are provided or 			e thought	ful comments that	you have	
Because we a					uscripts submitted soon as possible. I						#2 reviewe						
Emerg Med, y					unt of time, we ma												

REVISI KEDUA (21 FEB-19 MAR 2023)

~ ~				A \$\$		Ø
Clinical and To: Husna Put	Experimental Emergency Medicine	21/02/23	Clinical and Ex To: Husna Dharm	perimental Emerge na Putera >	ency Medicine	19/03/
anuscript ID vision	[CEEM-22-403] Letter of decision 2nd - Mi	nor	[2nd Revision co submitted	ompleted] CEE	EM-22-403 was revis	sed and
	[Clin Exp Emerg Med] Review result	t:2nd		[Clin Exp	Emerg Med] 2nd Revis	ion completed.
Date sent :	February 21, 2023			CEEM-22-403		
Date Decisioned	: February 21, 2023		Manuscript ID : Revision Date :	19-Mar-2023 22:08		
Manuscript ID :	CEEM-22-403		Type of Manuscript			
Title :	The impact of COVID-19 on mortality in trauma patients undergoing orthopaedic surgery: A systematic review and meta-analysis		Title :	The impact of COVID	D-19 on mortality in trauma patient : A systematic review and meta-an	
Corresponding Author :	Husna Putera		Corresponding Author :	Husna Dharma Puter		
Review result :	Minor revision (Revision Period : ~ 2023-3-21)		Author's opinion :	#1 reviewer:		
to Clin Exp En Based on the publication in reviewers. You your revised r of responses I addition to yo	ived the reports from the reviewers on your manuscript which you submitt	e ing list he		second review of this reviewer's comments 1. The results of the meta-analysis were 1 by Ma et al. in 2020 In table 1, in Ma et a simultaneously asses studies: the CASP ch tool we used (line 76 found that the JBI to we decided to use th evidence, we use the suggested by the #3 Table 3. Reference:	studies that we included in this sy 15 cohort studies and 1 cross-secti describes various tools that can as a ls study, it was found that three ss the risk of bias in the cohort ane cecklist, the NH quality assessme 5-77). In supplementary table 2 of ol has the fewest domains among is tool. To get consistent results as 6 GRADE approach (line 97-100) si 8 reviewer. We have attached the G	Ints in response to the vstematic review and ional study. An article seess the risk of bias. tools could d cross-sectional nt tool, and the JBI M ast al.'s study, we the other tools, so cross all bodies of ince it was also SRADE approach in
Emerg Med, y possible for y	re trying to facilitate timely publication of manuscripts submitted to <i>Clin E</i> rour revised manuscript should be uploaded as soon as possible. If it is not out o submit your revision in a reasonable amount of time, we may have t paper as a new submission.	t		quality (risk of bias) studies: what are the	Ig ZH, Huang D, Weng H, Zeng XT. assessment tools for primary and ey and which is better. Military Med 186/s40779-020-00238-8	secondary medical

ACCEPTANCE ARTIKEL

	4	m	N	_	~	
\sim \sim	5	 	W	E		
Clinical and To: Husna Put	Experimental era >	Emerger	псу Ме	dicine		29/03/2
lanuscript ID	[CEEM-22	2-403]	Lette	er of d	ecisio	n 3rd - Accept
			?			
		[Clin	Exp E	merg	Med] R	eview result : 3rd
Date sent :	March 29, 2023					
Date Decisioned	March 29, 2023					
Manuscript ID :	CEEM-22-403					
Title :	The impact of C orthopaedic sur					
Corresponding Author :	Husna Putera					
Review result :	Accept					
Comments to Authors (Editorial Office) :						
publication in Your manuscri returned to yo final version ti	rough the online	ed. d by Englis minor char submissior	h and/or nges nec n system	bibliogra essary. Ir as soon a	phic exper h that case as possible	rts and will be e, please return the e.
그는 그 관련가 앉은 이렇게 잘 집 같아요.	your important or tributions to the j		to Clin E	xp Emerg	<i>Med</i> . We	look forward to your
Sincerely,						
Adam J Singer Editor-in-Chie						
	g Med Editorial Of wnstone Seoul, 4		pa-ro, Ju	ng-gu, S	eoul 04510	0, Korea
TEL: +82-31- E-mail: office(709-0918 Dceemjournal.org	6				
L-mail. onice(sceenijournai.org	3				

Journal Pre-proofs This PDF file is not yet the definitive version. This version will undergo additional editing and correction before it is published in its final form.

Systematic Review

Received: 2022/11/25 Revised: 2023/03/19 Accepted: 2023/03/29

DOI: https://doi.org/10.15441/ceem.22.403

The impact of COVID-19 on mortality in trauma patients undergoing orthopedic surgery: a systematic review and meta-analysis

Abbreviated title: Orthopedic trauma surgery

Husna Dharma Putera¹, Valentina Halim², Roselina Panghiyangani³

¹Department of Orthopedic and Traumatology, Faculty of Medicine, Ulin General Hospital, Universitas

Lambung Mangkurat, Banjarmasin, Indonesia

²Siloam Hospital, Banjarmasin, Indonesia

³Biomedical Department, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia

Correspondence to: Husna Dharma Putera

Department of Orthopedic and Traumatology, Faculty of Medicine, Ulin General Hospital, Universitas Lambung Mangkurat, 43 Jalan Ahmad Yani, Banjarmasin 70233, Indonesia Email: hdputera@ulm.ac.id

ABSTRACT

Objective: The global spread of the COVID-19 pandemic has affected all aspects, including orthopedic trauma surgery. This study aims to investigate whether COVID-19–positive patients who underwent orthopedic surgery trauma had a higher risk of postoperative mortality.

Methods: ScienceDirect, the Cochrane COVID-19 Study Register, and MEDLINE were searched for original publications. This study adhered to the PPRISMA 2020 statement. The validity was evaluated using a checklist developed by the Joanna Briggs Institute. Study and participant characteristics, as well as the odds ratio, were extracted from selected publications. Data were analyzed using RevMan ver. 5.4.1.

Results: After applying the inclusion and exclusion criteria, 16 articles among 717 total were deemed eligible for analysis. Lower-extremity injuries were the most common condition, and pelvic surgery was the most frequently performed intervention. There were 456 COVID-19–positive patients (6.12%) and 134 deaths among COVID-19–positive patients, revealing a mortality escalation (29.38% vs. 5.30% among COVID-19–negative patients; odds ratio, 7.72; 95% confidence interval, 6.01–9.93; P<0.00001). **Conclusion:** Among COVID-19–positive patients, the postoperative death rate increased by 7.72 times. It may be possible to improve prognostic stratification and perioperative care by identifying risk factors.

Keywords: Wounds and injuries; Orthopedic procedures; COVID-19; Mortality

CAPSULE SUMMARY

What is already known

During the COVID-19 pandemic, there was a decrease in emergency room visits for trauma and surgical intervention, particularly in traumatology services.

What is new in the current study

This study analyzes the most recent literature on postoperative mortality in trauma patients undergoing orthopedic surgery during the COVID-19 pandemic.

INTRODUCTION

The World Health Organization (WHO) announced the discovery of a new condition, COVID-19, in early February 2020, before declaring a global pandemic in March 2020. The rapid global spread of the causative pathogen, SARS-CoV-2, has caused major changes to human life worldwide. Many countries in the Asia-Pacific region, including Australia, Korea, and Japan, were among the first to respond to the COVID-19 epidemic [1].

During the COVID-19 pandemic, emergency room visits decreased, particularly visits for trauma and surgical intervention in traumatology cases [2,3]. With this reduction in visits, patients more frequently received delayed care during the current pandemic [4]. Previous studies have shown that delaying surgery increases mortality and the risk of postoperative pneumonia in trauma patients [5].

The present study sought to conduct a systematic review and meta-analysis on postoperative mortality in COVID-19–positive and –negative patients undergoing orthopedic trauma surgery. The present meta-analysis sought to investigate the odds ratio (OR) of mortality in this patient population by comparing statistics between COVID-19–positive and –negative groups. We speculated that postoperative COVID-19–positive orthopedic trauma patients would have a higher risk of death than those negative for COVID-19.

METHODS

Search strategy and study selection

The protocol of this review was registered in PROSPERO (International Prospective Register of Systematic Reviews) on September 27, 2022 (No. CRD42022359112). In accordance with recent PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020 statement for identifying research through databases and registers, a systematic review of the mortality in orthopedic surgery owing to trauma during the COVID-19 pandemic was performed, as shown in Fig. 1 [6]. The phrases "orthopedic" AND "trauma" AND "surgery" AND "COVID-19" were used to search the ScienceDirect and MEDLINE (via PubMed) databases for English-language studies that reported mortality among both COVID-19–positive and –negative patients. The literature search was conducted on September 20, 2022. A search using MeSH (Medical Subject Headings) terms was carried out

whenever possible using the combination of the search 1 ("orthopedic trauma surgery" [MeSH Terms] OR "orthopedic trauma surgery" [All Fields]) AND search 2 ("COVID-19 [MeSH Terms] OR "COVID-19" [All Fields]) strategies.

Inclusion and exclusion criteria

We included observational studies like cohort, cross-sectional, and case–control studies but excluded review articles. The validity of the papers included in this study was evaluated using a series of inquiries based on a checklist in line with the kind of study created by the Joanna Briggs Institute [7,8], as shown in Supplementary Table 1 [9–23] and Supplementary Table 2 [24]. Articles that did not fit the requirements for inclusion were rejected. The inclusion criteria formulated according to the PICO mnemonic for clinical research questions were as follows: (1) P (patient, population, problem): patients of all ages who underwent orthopedic trauma surgery; (2) I (intervention, prognostic factor, or exposure): COVID-19 infection (positive or negative polymerase chain reaction result); (3) C (comparison or intervention): none; and (4) O (outcome): postoperative mortality.

Data synthesis

If possible, the data synthesis included information on patient mean age, sex, death rate, underlying disease, complications, intervention site, type of surgery, and hospital stay. The data were summarized in Microsoft Excel (Microsoft Corp) after their collection, and RevMan ver. 5.4.1 (Cochrane Collaboration) was used for statistical analysis. We performed planned subgroup analyses for the confounding variables, which included time points of patient outcome measurement (inpatient vs. 30-day follow-up) and age (<60 years vs. >60 years). Publication bias was measured by visual inspection of funnel plots and quantitatively using Egger test [25]. We considered findings significant if P<0.05. GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) scores were used to evaluate the certainty of the evidence for each outcome [26]. A GRADE summary of the findings in Table 3 was generated using GRADEpro (GradePro Inc) [27].

RESULTS

During the literature search, 717 studies were discovered. After removing duplicates, 691 studies remained, and 32 potentially relevant studies were chosen for eligibility examination. This metaanalysis included 16 observational studies (10 retrospective cohort studies, five prospective cohort studies, and one cross-sectional study). The majority of patients in these investigations were >60 years old. The study characteristics and postoperative mortality findings are shown in Table 1 [9–24]. The most common injury sites were the hip and femur, followed by other lower-limb sites such as the patella, tibia, ankle, foot, and upper limb. Supplementary Table 3 shows the types of injuries that required orthopedic surgery. Hemiarthroplasty, total hip arthroplasty, unspecified elective minor surgery, and open reduction and internal fixation of the femur were the major surgeries performed.

Five studies [15,18,20,21,24] compared the number of orthopedic surgeries performed during and before the start of the COVID-19 pandemic and discovered that the numbers of surgeries performed did not significantly differ. Nonetheless, postoperative mortality increased significantly during the pandemic.

During the COVID-19 pandemic, 7,795 injuries were reported (Supplementary Table 3), with 15 cases (0.19%) not being treated surgically. According to Table 1 [9–24], we identified 6,996 COVID-19–negative patients (93.89%) and 456 COVID-19–positive patients (6.11%) among the 7,452 operative patients who underwent COVID-19 testing via polymerase chain reaction testing of a nasopharyngeal swab. Meanwhile, 134 COVID-19–positive patients (29.38%) died after surgery compared to 5.30% of the COVID-19–negative group, despite the small number of COVID-19–positive patients. The mortality rate of COVID-19–positive patients ranged from 14.28% to 50% among included studies.

Complications due to COVID-19 were most commonly reported as the primary cause of postoperative death among COVID-19–positive patients. The reported primary causes of postoperative death, complications, underlying disease, and mean hospital stay in both groups are shown in Table 2 [9–24]. Eight studies [11–15,19,20,22] did not report the cause of death in their research.

A total of 1,616 reported surgeries from seven studies [13,16–18,20–22] are shown in Supplementary Table 4. In contrast, nine studies [9–12,14,15,19,23,24] did not specify the surgeries performed in their studies. Only Lim et al. [18] reported the type of anesthesia used in both groups.

Fig. 2 depicts the qualitative analysis of each study's funnel plot to determine the degree of asymmetry. Egger regression test was calculated with P=0.34. A funnel plot and Egger test showed no evidence of publication bias. As shown in Figs. 3–6 [9–24], we established a forest plot and subgroup analysis to illustrate the significance among all studies included in our meta-analysis. We analyzed the 16 trials and established a random-effects model, resulting in an overall OR of 7.72 (95% confidence interval [CI], 6.01–9.93; P<0.00001; I²=0%). As shown in Fig. 6 [13–15,17,23], the incidence of venous thromboembolism (VTE) was increased among COVID-19–positive patients (OR, 4.08; 95% CI, 1.23–13.58). According to these findings, COVID-19 positivity might increase the mortality rate and occurrence of thromboembolism in patients undergoing orthopedic surgery.

The test for subgroup differences in Figs. 4 and 5 [9–24] indicated a statistically significant subgroup effect (P<0.05) at inpatient (OR, 8.67; 95% CI, 5.82–12.91), 30-day follow-up (OR, 7.32; 95% CI, 4.30–12.49), and in patients with a mean age of >60 years (OR, 7.75; 95% CI, 6.02–9.97). Mortality in COVID-19–positive patients with a mean age of <60 years showed an increase in one study, but this increase was not statistically significant (OR, 5.75; 95% CI, 0.46–72.30; P = 0.18).

DISCUSSION

This systematic review and meta-analysis looked at the death rate among COVID-19–positive and – negative trauma patients undergoing orthopedic surgery. Most of the participants in this study were >60 years old. This finding is consistent with those of Atinga et al. [28], who found that geriatric trauma cases are increasing every year and now account for >25% of all significant trauma cases in the United Kingdom. Aging is associated with progressive physiological changes that affect various systems. Elderly people respond to trauma in a physiologically different manner than other people. Physiological responses in the elderly might vary due to co-occurring diseases, premorbid frailty, and prescribed drugs.

Previous research has linked hip fracture in the elderly to greater morbidity, a loss of autonomy in activities of daily living, a high rate of institutionalization, and mortality. Conservatively, mortality

after hip fracture surgery is high in the first year, being approximately 30% of all cases [29–31]. In this study, 70 of the 134 patients with postoperative deaths among 456 COVID-19–positive patients who underwent orthopedic surgery had a hip or femur fracture.

According to Supplementary Table 4, the most commonly performed procedure in this study was hip arthroplasty. Haskel et al. [32] discovered that hip fracture volume in the elderly did not decrease during the lockdown period, even in areas severely affected by COVID-19 outbreaks. Age, a large waist circumference, a lower skeletal muscle index, bone mass density, vitamin D level, physical function, nutritional status, and cognitive function are linked to hip fractures in the elderly [33,34].

VTE involves both pulmonary embolism and deep vein thrombosis, respectively, and occurs in 0.6% to 1.5% of patients undergoing total joint arthroplasty. The risk factors for VTE are described by Virchow triad, which are venous stasis, endothelial damage, and a hypercoagulable state. VTE is typically the result of the interaction of two or less causes. Venous stasis can occur both during and after surgery due to intraoperative immobilization. Prolonged immobility raises the possibility of VTE development [35].

Previous research found that COVID-19–positive patients had a higher mortality rate during hip and femur fracture surgery [36–39]. Surgery within 48 hours does not correlate with a lower mortality rate in COVID-19–positive patients [13]. As shown in Table 2 [9–24], the mean hospital stay length among COVID-19–positive patients undergoing hip and femur surgery was longer than that among COVID-19–negative patients. This result is in line with the study by Kayani et al. [37], which stated that hip surgery in COVID-19–positive patients was associated with a longer hospital stay, longer immobilization, more hospitalizations in the intensive care unit, an increased chance of peri-operative complications, and greater mortality rates. COVID-19–positive patients with a smoking history and multiple (>3) significant comorbidities have a higher risk of death. Identifying factors that contribute to a higher death rate may improve prognostic classification and interdisciplinary perioperative care.

This review has some limitations. The majority GRADE rating in Table 3 was low because the evidence came from observational studies. Inaccurate studies with smaller sample sizes of COVID-19– positive patients may be influenced by chance. Of the 16 studies, only nine provided information about the type of surgery performed, eight reported the primary cause of postoperative death, and just one

provided information about the type of anesthesia used in both groups. All of the included studies were conducted prior to the availability of COVID-19 vaccines.

In conclusion, the postoperative mortality rate among COVID-19–positive patients was 7.72 times greater than that of COVID-19–negative patients. Identifying risk factors for increased mortality may improve prognostic classification and perioperative interdisciplinary medication. The findings of this study should be considered by the larger orthopedic community when developing guidelines for treating orthopedic trauma in specific populations in the COVID-19 era.

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Joanna Briggs Institute risk of bias quality assessment for cohort studiesSupplementary Table 2. Joanna Briggs Institute risk of bias quality assessment for cross-sectional studies

Supplementary Table 3. Indications for orthopedic surgery during the COVID-19 pandemic Supplementary Table 4. The reported surgery in this study

Supplementary Material 1. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist.

Supplementary materials are available at https://doi.org/10.15441/ceem.22.403.

ETHICS STATEMENTS

Not applicable.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization: HDP; Formal analysis: VH, RP; Methodology: all authors; Project administration: HDP; Writing–original draft: HDP; Writing–review & editing: all authors. All authors read and approved the final manuscript.

ORCID

Husna Dharma Putera

https://orcid.org/0000-0002-5879-1242

Valentina Halim

Roselina Panghiyangani

Not available https://orcid.org/0000-0002-6233-1978

REFERENCES

- 1. Kurozumi T, Minehara H, Kim JW, Oh CW, Miclau EE, Balogh ZJ. Orthopaedic trauma care during the early COVID-19 pandemic in the Asia-Pacific region. OTA Int 2021;4(1 Suppl):e119.
- Pamungkas KM, Dewi PI, Dyatmika IK, Maharjana MA, Meregawa PF. The impact of the COVID-19 pandemic on trauma cases in the orthopedics and traumatology services: a systematic review. J Kedokt Kesehat Indones 2022;13:68–78.
- 3. Nunez JH, Sallent A, Lakhani K, et al. Impact of the COVID-19 pandemic on an emergency traumatology service: experience at a tertiary trauma centre in Spain. Injury 2020;51:1414–8.
- 4. Haleem A, Javaid M, Vaishya R, Vaish A. Effects of COVID-19 pandemic in the field of orthopaedics. J Clin Orthop Trauma 2020;11:498–9.
- 5. Simunovic N, Devereaux PJ, Sprague S, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ 2010;182:1609–16.
- 6. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- JBI. Critical appraisal tools for use in JBI systematic reviews: checklist for cohort studies [Internet].
 JBI; 2020 [cited 2022 Sep DATE]. Available from: <u>https://jbi.global/critical-appraisal-tools</u>
- BI. Critical appraisal tools for use in JBI systematic reviews: checklist for analytical cross sectional studies [Internet]. JBI; 2020 [cited 2022 Sep DATE]. Available from: <u>https://jbi.global/critical-appraisal-tools</u>
- 9. Andrzejowski PA, Howard A, Vun JSH, et al. COVID-19: the first 30 days at a UK level 1 trauma centre and lessons learnt. Cureus 2020;12:e11547.
- Beaven A, Piper D, Plant C, Sharma A, Agrawal Y, Cooper G. Thirty-day mortality for proximal femoral fractures treated at a U.K. elective center with a site-streaming policy during the COVID-19 pandemic. JB JS Open Access 2021;6:e21.00009.
- 11. Balakumar B, Nandra RS, Woffenden H, et al. Mortality risk of surgically managing orthopaedic trauma during the COVID-19 pandemic. Bone Jt Open 2021;2:330–6.
- 12. Clement ND, Hall AJ, Makaram NS, et al. IMPACT-Restart: the influence of COVID-19 on postoperative mortality and risk factors associated with SARS-CoV-2 infection after orthopaedic and

trauma surgery. Bone Joint J 2020;102-B:1774-81.

- 13. Dallari D, Zagra L, Cimatti P, et al. Early mortality in hip fracture patients admitted during first wave of the COVID-19 pandemic in Northern Italy: a multicentre study. J Orthop Traumatol 2021;22:15.
- Egol KA, Konda SR, Bird ML, et al. Increased mortality and major complications in hip fracture care during the COVID-19 pandemic: a New York City perspective. J Orthop Trauma 2020;34:395– 402.
- 15. Fisher ND, Bi AS, Aggarwal V, Leucht P, Tejwani NC, McLaurin TM. A Level 1 Trauma Center's response to the COVID-19 pandemic in New York City: a qualitative and quantitative story. Eur J Orthop Surg Traumatol 2021;31:1451–6.
- 16. Hall AJ, Clement ND, Farrow L, et al. IMPACT-Scot report on COVID-19 and hip fractures. Bone Joint J 2020;102-B:1219–28.
- 17. LeBrun DG, Konnaris MA, Ghahramani GC, et al. Hip fracture outcomes during the COVID-19 pandemic: early results from New York. J Orthop Trauma 2020;34:403–10.
- 18. Lim JA, Thahir A, Amar Korde V, Krkovic M. The impact of COVID-19 on neck of femur fracture care: a major trauma centre experience, United Kingdom. Arch Bone Jt Surg 2021;9:453–60.
- 19. Pass B, Vajna E, Knauf T, et al. COVID-19 and proximal femur fracture in older adults: a lethal combination?: an analysis of the registry for geriatric trauma (ATR-DGU). J Am Med Dir Assoc 2022;23:576–80.
- Sobti A, Memon K, Bhaskar RR, Unnithan A, Khaleel A. Outcome of trauma and orthopaedic surgery at a UK District General Hospital during the COVID-19 pandemic. J Clin Orthop Trauma 2020;11(Suppl 4):S442–5.
- 21. Thakrar A, Chui K, Kapoor A, Hambidge J. Thirty-day mortality rate of patients with hip fractures during the COVID-19 pandemic: a single centre prospective study in the United Kingdom. J Orthop Trauma 2020;34:e325–9.
- 22. Wright EV, Musbahi O, Singh A, Somashekar N, Huber CP, Wiik AV. Increased perioperative mortality for femoral neck fractures in patients with coronavirus disease 2019 (COVID-19): experience from the United Kingdom during the first wave of the pandemic. Patient Saf Surg

2021;15:8.

- 23. Zajonz D, Vaitl P, Edel M, et al. Effects of SARS-CoV-2 infections on inpatient mortality of geriatric patients after proximal femoral fracture surgery. Orthopadie (Heidelb) 2022;51:573–9.
- 24. Greensmith TS, Faulkner AC, Davies PS, et al. Hip fracture care during the 2020 COVID-19 firstwave: a review of the outcomes of hip fracture patients at a Scottish Major Trauma Centre. Surgeon 2021;19:e318–24.
- 25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- 26. Schunemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations [Internet]. The GRADE Working Group; 2013 [cited 2022 Sep DATE]. Available from: <u>https://guidelinedevelopment.org/handbook</u>
- 27. GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University and Evidence Prime; 2022. Available from: https://www.gradepro.org
- 28. Atinga A, Shekkeris A, Fertleman M, Batrick N, Kashef E, Dick E. Trauma in the elderly patient. Br J Radiol 2018;91:1087.
- 29. Civinini R, Paoli T, Cianferotti L, et al. Functional outcomes and mortality in geriatric and fragility hip fractures: results of an integrated, multidisciplinary model experienced by the "Florence hip fracture unit". Int Orthop 2019;43:187–92.
- 30. Mariconda M, Costa GG, Cerbasi S, Recano P, Aitanti E, Gambacorta M, Misasi M. The determinants of mortality and morbidity during the year following fracture of the hip: a prospective study. Bone Joint J 2015;97-B:383–90.
- 31. Downey C, Kelly M, Quinlan JF. Changing trends in the mortality rate at 1-year post hip fracture: a systematic review. World J Orthop 2019;10:166–75.
- 32. Haskel JD, Lin CC, Kaplan DJ, et al. Hip fracture volume does not change at a New York City level
 1 trauma center during a period of social distancing. Geriatr Orthop Surg Rehabil
 2020;11:2151459320972674.
- 33. Liu LK, Lee WJ, Chen LY, et al. Association between frailty, osteoporosis, falls and hip fractures among community-dwelling people aged 50 years and older in Taiwan: results from I-Lan

Longitudinal Aging Study. PLoS One 2015;10:e0136968.

210

- 34. Steingrimsdottir L, Halldorsson TI, Siggeirsdottir K, et al. Hip fractures and bone mineral density in the elderly: importance of serum 25-hydroxyvitamin D. PLoS One 2014;9:e91122.
- 35. Santana DC, Emara AK, Orr MN, et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina (Kaunas) 2020;56:416.
- 36. Freitas T, Ibrahim A, Lourenco A, Chen-Xu J. Mortality in COVID-19 patients after proximal femur fracture surgery: a systematic review and meta-analysis. Hip Int 2022 Aug 12 [Epub]. https://doi.org/10.1177/11207000221116764
- 37. Kayani B, Onochie E, Patil V, et al. The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fractures. Bone Joint J 2020;102-B:1136-45.
- 38. Levitt EB, Patch DA, Mabry S, et al. Association between COVID-19 and mortality in hip fracture surgery in the National COVID Cohort Collaborative (N3C): a retrospective cohort study. J Am Acad Orthop Surg Glob Res Rev 2022;6:e21.00282.
- 39. Wang KC, Xiao R, Cheung ZB, Barbera JP, Forsh DA. Early mortality after hip fracture surgery in COVID-19 patients: a systematic review and meta-analysis. J Orthop 2020;22:584–91.

FIGURE LEGENDS




Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 statement flowchart of the search strategy and selection of studies.




Fig. 2. No publication bias is visible in the funnel plot of the selected studies. This figure displays the qualitatively evaluated asymmetry findings from each study. SE, standard error; OR, odds ratio.

	COVID-	19 +	COVID	-19 -		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Andrzejowski et al	4	12	4	150	2.6%	18.25 [3.84, 86.67]	
Balakumar et al	19	43	11	146	8.5%	9.72 [4.11, 22.96]	
Beaven et al	9	40	8	145	5.9%	4.97 [1.78, 13.91]	
Clement et al	22	68	63	1501	19.6%	10.92 [6.19, 19.25]	
Dallari et al	8	53	7	424	5.6%	10.59 [3.67, 30.57]	
Egol et al	6	17	1	107	1.3%	57.82 [6.37, 525.04]	
Fisher et al	2	10	1	24	1.0%	5.75 [0.46, 72.30]	
Greensmith et al	2	5	5	84	1.6%	10.53 [1.42, 78.18]	
Hall et al	9	25	24	278	7.5%	5.95 [2.38, 14.90]	→
LeBrun et al	3	7	1	40	1.0%	29.25 [2.43, 351.43]	
Lim et al	1	7	7	85	1.2%	1.86 [0.19, 17.69]	
Pass et al	32	123	214	3610	34.7%	5.58 [3.65, 8.54]	
Sobti et al	3	6	5	47	1.8%	8.40 [1.32, 53.40]	
Thakrar et al	4	12	1	6	1.0%	2.50 [0.21, 29.25]	
Wright et al	5	16	3	50	2.5%	7.12 [1.47, 34.39]	
Zajonz et al	5	12	16	299	4.0%	12.63 [3.61, 44.24]	
Total (95% CI)		456		6996	100.0%	7.72 [6.01, 9.93]	•
Total events	134		371				
Heterogeneity: Tau ² =	: 0.00; Chi	² = 13.8	7, df = 15	5 (P = 0	.54); l² = ()%	0.002 0.1 1 10 500
Test for overall effect:							0.002 0.1 1 10 500 COVID-19 - COVID-19 +

Fig. 3. Forest plot of all the articles included in this study. M-H, Mantel-Haenszel test; Random, random-effects model; CI, confidence interval.

INPATIENT	COVID-	19 +	COVID	-19 -		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	I M-H, Random, 95% Cl
Andrzejowski et al	4	12	4	150	5.7%	18.25 [3.84, 86.67]]
Beaven et al	9	40	8	145	11.1%	4.97 [1.78, 13.91]] – –
Clement et al	22	68	63	1501	23.0%	10.92 [6.19, 19.25]] –
Dallari et al	8	53	7	424	10.6%	10.59 [3.67, 30.57]] – – –
Egol et al	6	17	1	107	3.0%	57.82 [6.37, 525.04]]
LeBrun et al	3	7	1	40	2.4%	29.25 [2.43, 351.43]]
Lim et al	1	7	7	85	2.9%	1.86 [0.19, 17.69]]
Pass et al	32	123	214	3610	28.8%	5.58 [3.65, 8.54]] – –
Sobti et al	3	6	5	47	4.2%	8.40 [1.32, 53.40]] — — — — — — — — — — — — — — — — — — —
Zajonz et al	5	12	16	299	8.2%	12.63 [3.61, 44.24]]
Total (95% CI)		345		6408	100.0%	8.67 [5.82, 12.91]	ı
Total events	93		326				· · · · · · · · · · · · · · · · · · ·
Heterogeneity: Tau ² =	0.10; Chi	i ² = 12.3	31, df = 9	(P = 0.2)	$(0); I^2 = 27$	7%	0.002 0.1 1 10 500
Test for overall effect:	Z = 10.61	(P < 0.	00001)				COVID-19 - COVID-19 +
							0000-13- 0000-13-
30-DAY	COVID-	10 .	COVID	10		Odds Ratio	Odds Ratio
	Events				Moight	M-H, Random, 95% Cl	
Study or Subgroup							
Balakumar et al	19	43	11	146	38.5%	9.72 [4.11, 22.96]	
Fisher et al	2	10	1	24	4.4%	5.75 [0.46, 72.30]	-
Greensmith et al	2	5	5	84	7.1%	10.53 [1.42, 78.18]	-
Hall et al	9	25	24	278	33.8%	5.95 [2.38, 14.90]	-
Thakrar et al	4	12	1	6	4.7%	2.50 [0.21, 29.25]	
Wright et al	5	16	3	50	11.5%	7.12 [1.47, 34.39]	
Total (95% CI)		111		588	100.0%	7.32 [4.30, 12.49]	I 🔶
Total events	41		45				
Heterogeneity: Tau ² =	: 0.00; Chi	i ² = 1.51	, df = 5 (F	° = 0.91); l² = 0%		
Test for overall effect:	Z=7.31 ((P < 0.0	0001)				COVID-19 - COVID-19 +

Fig. 4. Postoperative mortality of (A) At inpatient and (B) 30-day follow-up. M-H, Mantel-Haenszel

test; Random, random-effects model; CI, confidence interval.

>60 YEARS	COVID-		COVID		Mainht	Odds Ratio	Odds Ratio
Study or Subgroup	Events		Events			M-H, Random, 95% Cl	
Andrzejowski et al	4	12	4	150	2.6%	18.25 [3.84, 86.67]	
Balakumar et al	19	43	11	146	8.6%	9.72 [4.11, 22.96]	
Beaven et al	9	40	8	145	6.0%	4.97 [1.78, 13.91]	
Clement et al	22	68	63	1501	19.8%	10.92 [6.19, 19.25]	
Dallari et al	8	53	7	424	5.7%	10.59 [3.67, 30.57]	
Egol et al	6	17	1	107	1.3%	57.82 [6.37, 525.04]	
Greensmith et al	2	5	5	84	1.6%	10.53 [1.42, 78.18]	
Hall et al	9	25	24	278	7.6%	5.95 [2.38, 14.90]	
LeBrun et al	3	7	1	40	1.0%	29.25 [2.43, 351.43]	
Lim et al	1	7	7	85	1.3%	1.86 [0.19, 17.69]	
Pass et al	32	123	214	3610	35.1%	5.58 [3.65, 8.54]	
Sobti et al	3	6	5	47	1.9%	8.40 [1.32, 53.40]	
Thakrar et al	4	12	1	6	1.1%	2.50 [0.21, 29.25]	
Wright et al	5	16	3	50	2.6%	7.12 [1.47, 34.39]	
Zajonz et al	5	12	16	299	4.1%	12.63 [3.61, 44.24]	
Total (95% CI)		446		6972	100.0%	7.75 [6.02, 9.97]	•
Total events	132		370				
Heterogeneity: Tau ² =	0.00; Chi	² = 13.8	2, df = 14	(P = 0)	.46); l ² = ()%	0.002 0.1 1 10 500
Test for overall effect:	Z = 15.91	(P < 0.	00001)				0.002 0.1 1 10 500 COVID-19 - COVID-19 +
<60 YEARS	COVID-	19 +	COVID	19 -		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Fisher et al	2	10	1	24	100.0%	5.75 [0.46, 72.30]	
Total (95% CI)		10		24	100.0%	5.75 [0.46, 72.30]	
Total events	2		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:		P = 0.1	8)				0.01 0.1 1 10 100 COVID-19 - COVID-19 +

Fig. 5. Postoperative mortality in the patients with a mean age of (A) >60 years and (B) <60 years. M-

H, Mantel-Haenszel test; Random, random-effects model; CI, confidence interval.

e'e'

VTE	COVID-	19 +	COVID-	-19 -		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Dallari et al	0	53	2	424	15.5%	1.58 [0.07, 33.34]			
Egol et al	2	17	3	107	41.3%	4.62 [0.71, 29.97]		+	
Fisher et al	2	10	0	24	14.7%	14.41 [0.63, 331.31]			
LeBrun et al	0	7	1	40	13.3%	1.76 [0.07, 47.33]			-
Zajonz et al	0	12	2	299	15.1%	4.76 [0.22, 104.47]			
Total (95% CI)		99		894	100.0%	4.08 [1.23, 13.58]		-	?
Total events	4		8						
Heterogeneity: Tau ² =	= 0.00; Chi	² = 1.28	, df = 4 (F	P = 0.86	5); I ² = 0%				
Test for overall effect	Z = 2.29 ((P = 0.0)	2)				0.005	0.1 1 10 COVID-19 - COVID-19 +	200

Fig. 6. Occurrence of venous thromboembolism in COVID-19-positive and -negative groups. M-H,

Mantel-Haenszel test; Random, random-effects model; CI, confidence interval.

Table 1. Study characteristics and postoperative mortality

Study	Study period	Study design	Study location	Age (yr)	Female sex	Intervention location	Covid-	19 (+)	Covid	-19 (-)	Follow- up
							Mortality (n=134, 29.38%)	Total surgery (n=456)	Mortality (n=371, 5.30%)	Total surgery (n=6,996)	_ up
Andrzejowski et al. [9]	March 23, 2020–April 22, 2020 (1 mo)	Prospective	UK	60.7 (1–98)	88	Upper limb, hip, lower limb, and other trauma	4 (33.33)	12	4 (2.66)	150	Inpatient
Balakumar et al. [11]	March 26, 2020–May 20, 2020 (56 day)	Prospective	UK	65.0	Not reported	Clavicula, upper limb, hip, lower limb, and other trauma	19 (44.18)	43	11 (7.53)	146	30-day
Beaven et al. [10]	March 28, 2020–May 25, 2020 (59 day)	Prospective	UK	83.0 (76–90)	Not reported	Proximal femur	9 (22.50)	40	8 (5.51)	145	Inpatient
Clement et al. [12]	March 1, 2020–April 19, 2020 (50 day)	Retrospective	Edinburg, UK	60.0 (14–102)	850	Upper limb, hip, lower limb, and other trauma	22 (32.35)	68	63 (4.19)	1,501	Inpatient
Dallari et al. [13]	March 8, 2020–May 4, 2020 (58 day)	Retrospective	Italy	83.3	381	Hip	8 (15.09)	53	7 (1.65)	424	Inpatient
Egol et al. [14]	February 1, 2020–April 15, 2020 (75 day)	Prospective	New York, USA	83.0	78	Hip	6 (35.29)	17	1 (0.93)	107	Inpatient
Fisher et al. [15]	March 16, 2020–May 15, 2020 (61 day)	Retrospective	New York, USA	58.0	10	Not reported	2 (20.0)	10	1 (4.16)	24	30-day
Greensmith et al. [24]	March 14, 2020–May 28, 2020 (76 day)	Cross-sectional	UK 🔷	81.6 (51–103)	Not reported	Hip	2 (40.0)	5	5 (5.95)	84	30-day
Hall et al. [16]	March 1, 2020–April 15, 2020 (46 day)	Retrospective	UK	80.0 (50–101)	Not reported	Hip	9 (36.0)	25	24 (8.63)	278	30-day
LeBrun et al. [17]	March 20, 2020–April 24, 2020 (36 day)	Retrospective	New York, USA	85.0 (65–100)	Not reported	Hip	3 (42.85)	7	1 (2.50)	40	Inpatient
Lim et al. [18] Pass et al. [19]	March 1, 2020–May 15, 2020 (76 day) July 1, 2020–December 31, 2020 (6 mo)	Retrospective Retrospective	UK Germany, Austria, and Switzerland	84.9 85.0 (80–89)	70 2,678	Neck of femur Proximal femur	1 (14.28) 32 (26.01)	7 123	7 (8.23) 214 (0.61)	85 3,610	Inpatient Inpatient
Sobti et al. [20] Thakrar et al. [21] Wright et al. [22]	March 1, 2020–May 31, 2020 (3 mo) March 15, 2020–April 15, 2020 (1 mo) March 11, 2020–April 30, 2020 (41 day)	Prospective Retrospective	UK UK UK	83.5 81.6 (54–100) 81.1 (38–98)	Not reported Not reported	Neck of femur Hip Neck of femur	3 (50.0) 4 (33.0) 5 (31.25)	6 12	5 (10.63) 1 (16.60) 2 (16.67)	47 6 50	Inpatient 30-day 30-day
Zajonz et al. [23]	January 1, 2020–January 31, 2021 (1 yr)	Retrospective Retrospective	UK Germany	81.1 (38–98) 82.0	Not reported 219	Proximal femur	5 (31.25) 5 (41.67)	16 12	3 (16.67) 16 (5.35)	50 299	30-day Inpatient

Values are presented as mean (range), number only, or number (%).

Study	Total postoperative mortality	COVID-19 (+)			COVID-19 (-)			Venous thromboembolism incidence		Mean hospital stay (day)	
		Primary cause of postoperative death	Underlying disease	Complication	Primary cause of postoperative death	Underlying disease	Complication	COVID-19 (+)	COVID-19 (-)	COVID-19 (+)	COVID-19 (-)
Andrzejowski et al. [9]	8	4 Complications due to COVID-19	1 COPD 2 Diabetes 1 Lung cancer 1 Autoimmune disease 1 Prostate cancer 1 Lymphoma	Not reported	1 Pneumonia 1 t-ICH 1 Sepsis 1 Record unavailable	1 COPD 2 Diabetes 1 Lung cancer 2 Stroke 1 Hypothyroidism 1 IHD 1 Heart failure 1 CKD 1 AF	Not reported	Not reported	Not reported	Not reported	Not reported
Balakumar et al. [11]	17	 5 Respiratory failures 2 Deliriums 1 Pneumonia 1 NOF fracture 	Not reported	Not reported	1 Respiratory failure 1 Pneumonia 1 Old age 1 Sepsis 4 Records unavailable	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Beaven et al. [10]	30	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Clement et al. [12]	85	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Dallari et al. [13]	15	Not reported	Not reported	16 Acute anemias 6 Pneumonias 6 Other respiratory complications 3 AHFs 2 UTIs 1 ARF	Not reported	Not reported	 138 Acute anemias 7 Pneumonias 8 Other respiratory complications 9 AHFs 7 UTIs 2 ARFs 3 Sepsis 2 PEs 2 Ictus cerebri 27 Other minor complications 	0	2	14.7	10.9

Table 2. Incidence of venous thromboembolism, underlying disease, complications, and length of hospital stay in COVID-19–positive and –negative groups.

Egol et al. [14]	7	Not reported	 8 Cardiovascular diseases (excluding hypertension) 11 Hypertensions 11 Immunocompromised state 7 Diabetes 4 ARFs 9 Hyperlipidemias 6 Dementias 	 3 Sepsis 2 Bacterial pneumonias 10 Viral pneumonias 2 PEs 2 MIs 7 ARDSs 2 Cardiac arrests 3 ARFs 7 Anemias 7 Hypotensions 6 AFs 	Not reported	 40 Cardiovascular diseases (excluding hypertension) 67 Hypertensions 4 Immunocompromised states 20 Diabetes 8 ARFs 38 Hyperlipidemias 27 Dementias 	3 Sepsis 1 Bacterial pneumonia 3 PEs 3 MIs 2 Strokes 2 ARDSs 8 ARFs 6 UTIs 35 Anemias 13 Hypotensions 12 AFs	2	3	9.8	5
Fisher et al. [15]	3	Not reported	Not reported	 Cardiac arrest Postoperative anemias ARDS PE/DVTs Pneumonias MI 	Not reported	Not reported	 Cardiac arrest Postoperative anemias ARDS Pneumonia Sepsis UTI 	2	0	9	7.91
Greensmith et al. [24]	7	2 Complications due to COVID-19	Not reported	Not reported	1 Complication from disseminated malignancy 1 UGIB 1 SUO 1 Urosepsis 1 Stroke	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Hall et al. [16]	33	9 Complications due to COVID-19	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
LeBrun et al. [17]	4	3 Complications due to COVID-19	3 Hypertensions 2 Hyperlipidemias 2 Diabetes 1 Osteoporosis 2 Dementias 1 Malignancy 1 PUD 1 GERD 1 BPH	6 Pneumonias 1 Arrhythmia 2 UTIs	1 Intraoperative cardiac arrest	1 CAD 1 AF 1 Hypertension 1 Hyperlipidemia 1 Diabetes 1 Hypothyroidism 1 CKD	5 Pneumonias 7 UTI 1 DVT 1 MI 2 Decubitus ulcers	0	1	8	6

Lim et al. [18]	8	1 Complication due to COVID-19	 Asthma Other lung disease Cardiovascular diseases Malignancies Diabetes Renal diseases Dementia 	Not reported	Not reported	 5 Asthmas 6 COPDs 12 Other lung diseases 54 Cardiovascular diseases 30 Malignancies 14 Diabetes 19 Renal diseases 16 Dementias 	Not reported	Not reported	Not reported	30.3	12
Pass et al. [19]	246	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	19.1	15.1
Sobti et al. [20]	8	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Thakrar et al. [21]	5	4 Complications due to COVID-19	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Wright et al. [22]	8	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	17	10
Zajonz et al. [23]	21	5 Complications due to COVID-19	Not reported	Not reported	 7 Cardiac decompensation with myocardial failures 2 PEs 2 Pneumonias 1 MI 1 Sepsis 1 GI bleeding 1 Epileptic shock with aspiration 1 Hepatic failure 	Not reported	Not reported	0	2	15.6	11.5

COPD, chronic obstructive pulmonary disease; t-ICH, traumatic intracranial hemorrhage; IHD, ischemic heart disease; CKD, chronic kidney disease; AF, atrial fibrillation; NOF, neck of femur; AHF, acute heart failure; UTI, urinary tract infection; ARF, acute renal failure; PE, pulmonary embolism; MI, myocardial infarction; ARDS, acute respiratory distress syndrome; DVT, deep vein thrombosis; UGIB, upper gastrointestinal bleeding; SUO, sepsis of unknown origin; PUD, peptic ulcer disease; GERD, gastroesophageal reflux disease; BPH, benign prostatic hyperplasia; CAD, coronary artery disease; GI, gastrointestinal;

Table 3. GRADE summary of findings

Outcome	Anticipated ab (95%		Relative effect OR (95% CI)	No. of participants	No. of observational studies	Certainty of the evidence (GRADE)
-	Risk with COVID-19 (-) (per 100)	Risk with COVID-19 (+) (per 100)				· · · ·
Overall mortality	5	30 (25–36)	7.72 (6.01–9.93)	7,452	16	Low
Postoperative mortality at inpatient	5	32 (24–41)	8.67 (5.82–12.91)	6,753	10	Low
Postoperative mortality at 30- day follow-up	8	38 (26–51)	7.32 (4.30–12.49)	699	6	Very low ^{b)}
Postoperative mortality in the patients with a mean age of >60 yr	5	30 (25–36)	7.75 (6.02–9.97)	7,418	15	Low
Postoperative mortality in the patients with a mean age of <60 yr	4	20 (2–76)	5.75 (0.46–72.30)	34	1	Very low ^{c)}
Venous thromboembolism incidence	1	4 (1–11)	4.08 (1.23–13.58)	993	5	Low

GRADE, Grading of Recommendations, Assessment, Development, and Evaluation; CI, confidence interval; OR, odds ratio.

7

^{a)}The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ^{b)}One study had a high risk of bias and two studies had moderate risk of bias. ^{c)}The 95% CI crosses the line of no effect and has an insufficient sample to meet the optimal information size criteria.